The global vaccine manufacturing landscape, I think, is coming into full view at the moment.
As with all these things, the devil is always in the details, and I don't know the particularities of what's in the licensing agreements or the collaboration agreement. Certainly I know there's near-global consensus that no one manufacturer is going to be in a position to mass-manufacture doses of this vaccine or of any vaccine.
I think the key point here is that the only way of ensuring sufficient quantities of vaccine or indeed of therapeutics for COVID-19 is going to be through a disseminated strategy of having multiple manufacturers in multiple countries producing quantities of these vaccines and medicines.
We're going to have to collaborate to have equitable distribution and allocation of all these medical tools. There's no logistical alternative. Everybody in the world who is working on this right now is discovering this reality.